Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 12
Submit an article Journal homepage
280
Views
5
CrossRef citations to date
0
Altmetric
Letters to the Editor

Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) – a new perspective

Sumeet Mirgha Adult Hematolymphoid and BMT unit, Tata Memorial Centre, ACTREC (Advanced Centre for Treatment, Research, and Education in Cancer), Navi Mumbai, India (Present Affiliation); Homi Bhabha National Institute, Mumbai, India (Present Affiliation); Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0642-2207
ORCID Icon,
Archana Sharmab Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Bhaarat Folbsb Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Vishvdeep Khushoob Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Jyotsna Kapoorb Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Narender Tejwanib Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Rayaz Ahmedb Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Narendra Agrawalb Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Partha S. Choudharyc Department of Nuclear Medicine, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
,
Pallavi Mehtab Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
&
Dinesh Bhuranib Department of Hematology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India
 show all
Pages 3039-3042 | Received 25 Apr 2021, Accepted 31 May 2021, Published online: 21 Jun 2021

References

  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hematopoietic and lymphoid tissues, Revised 4th edn, volume 2. Lyon: IARC Press; 2016.
  • Marafioti T, Paterson JC, Ballabio E, et al. Novel markers of normal and neoplastic human plasmacytoid dendritic cells. Blood. 2008;111(7):3778–3792.
  • Deotare U, Yee KWL, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with a leukemic presentation: 10-color flow cytometri diagnosis and hyperCVAD therapy. Am J Hematol. 2016;91(3):283–286.
  • De Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848.
  • Krejcik J, Casneuf T, Nijhof I, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
  • Poret E, Vidal C, Desbrosses Y, et al. American Society of Hematology 57th annual meeting and exposition. Orlando FL; 2015 Dec 5–8. Available from: https://ash.confex.com/ash/2015/webprogramscheduler/Paper81980.html.
  • Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;2016(1):16–23.
  • Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2018;379(15):1479–1481.
  • Pemmaraju N, Konopleva M, Lane AA. More on blastic plasmacytoid dendritic-cell neoplasms. N Engl J Med. 2019;380(7):695–696
  • DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018;93(3):401–407.
  • Grant S. Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies. Leuk Lymphoma. 2018;59(6):1292–1299.
  • Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
  • Iversen KF, Holdgaard PC, Preiss B, et al. Daratumumab for treatment of blastic plasmacytoid dendritic cell neoplasm. A single-case report. Haematologica. 2019;104(9):e432–e433.
  • Jen EY, Gao X, Li L, et al. FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26(3):532–536.
  • Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm. N Engl J Med. 2019;380(17):1628–1637.
  • Mirgh S, Ahmed R, Agrawal N, et al. Will Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol. 2019;187(2):e33–e35.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.